CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacy benefit manager CVS is considering a range of drugs and indications for the program, noting some oncology approvals in the coming months may be eligible.
You may also be interested in...
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use
A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.